Navigation Links
Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
Date:1/12/2009

30 total patients will be treated.

New Alliance for Use of Quadra-Fuse, Multi-pronged Injection Needles

Jennerex also announced today an alliance with Rex Medical, a manufacturer of advanced multi-pronged needles, for the targeted intratumoral administration of JX-594. Jennerex shall exclusively use Rex Medical Quadra-Fuse needles ("QF Needles") for intratumoral injections of JX-594 in clinical development, and Rex Medical shall work collaboratively with Jennerex to effectively apply this technology to JX-594 clinical development.

"We are excited to be collaborating with Rex Medical, the market leader in this field, for application of Quadra-Fuse needle technology with JX-594. This is the first needle designed for optimizing therapeutic delivery of fluids/agents into target tissue zones. This innovative multi-pronged design allows us to precisely target distribution of JX-594 for optimal therapeutic effect. The result is an innovative and potentially landmark combination of a highly targeted biotherapeutic agent with a sophisticated medical device for targeted delivery," stated Dr. Kirn.

About JX-594

JX-594 is a cancer biotherapeutic product, currently in Phase 2 trials, from a proprietary breakthrough class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types on three Phase 1 trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated. Normal cells are not affected by JX-594 resulting in safety and tolerability. The poxvirus strain backbone of JX-594 has
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
2. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
3. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
4. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
5. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
6. New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
7. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
10. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014   Stone ... settlement of off-label marketing and fraud claims between ... Vascular Solutions, Inc. ("VSI").  The settlement covers fraud ... devices for endovenous laser ablation of varicose veins ... a firm with a history of representing whistleblowers ...
(Date:7/28/2014)... 28, 2014  Surgical Theater, LLC announced today ... Business Advisory Board. New members include Ori ... Business Development and New Technologies for Given Imaging ... Senior Vice President and General Manager of Philips ... flight simulation technology to brain surgery and has ...
(Date:7/28/2014)... 2014 Southern Research Institute today announced ... and CEO of Southern Research Institute, has been ... for the 2014-2015 term.  The inauguration took place ... in Chicago with attendees ... The Controlled Release Society is an international, interdisciplinary, ...
Breaking Medicine Technology:Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3
... NEW YORK , Aug. 2 As eyewear is increasingly ... a series of new television commercials for those who have lost sight of ... deliver. , , , ... reminder: "Unless the glasses can perform miracles, don,t pay more than you have ...
... 2 ORBIS International is pleased to announce the appointment of Dr. ... Board of Directors. , , , ... Dr. Robert Walters has been an active member of ... the Board of Directors of ORBIS UK since 2003 and Chairman of ...
Cached Medicine Technology:For Eyes Optical Takes Man to Places He's Never Been Before in Humorous New TV Campaign 2For Eyes Optical Takes Man to Places He's Never Been Before in Humorous New TV Campaign 3Robert F. Walters Appointed Chairman of the Board of Directors of ORBIS International 2Robert F. Walters Appointed Chairman of the Board of Directors of ORBIS International 3
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
(Date:7/28/2014)... revised version of a surgical procedure to treat severe ... than 90 percent of the time in patients treated ... MGH Division of Plastic and Reconstructive Surgery report that ... non-endoscopic procedure all of whom had headaches associated ... relief a year later. The team,s paper has ...
(Date:7/28/2014)... Thousands of DePuy Pinnacle hip lawsuits ... who were allegedly injured by a metal-on-metal version of ... in U.S. District Court, Northern District of Texas, Bernstein ... July 18, 2014, U.S. District Judge Ed Kinkeade has ... Steering Committee that sought the deposition of a witness ...
(Date:7/28/2014)... July 28, 2014 Glutamine is the ... it’s considered to be conditionally essential during times when ... an advanced recovery & Immune System Support. , Having ... your body produces, supplementing with additional glutamine may be ... products in the body, digestion and immune system function. ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Ticket Down ... Colombia tickets in Miami, FL at the Sun Life ... South American football between Argentina and Brazil has is one ... stronger worldwide, more rivalries are forming on a consistent basis. ... reached a new height in the recent 2014 World Cup. ...
Breaking Medicine News(10 mins):Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3
... 29, 2008 A protein that helps keep immune ... of patients with multiple sclerosis (MS), further boosting suspicion ... to the disease. , More of an immune-control protein ... symptoms are caused by misdirected immune attacks on the ...
... Pa., Sept. 29 Herley Industries,Inc. (Nasdaq: ... England division in,Woburn, Massachusetts, has a contract totaling ... NY, for the manufacture of,complex switch filter assemblies ... ("ESM") system., The MH-60R Multi-Mission Helicopter (MMH) ...
... Hospital Affiliates , ... Alpharetta, GA ... Atlanta based healthcare staffing and technology firm, has created a ... Affiliates is to acquire community hospitals and apply the firm,s ...
... accident practice area that will provide victims of these costly and ... overcome the severity of the incident. The truck accident injury information ... recent jury verdicts. , ... Denver, CO (PRWEB) September ...
... dental clinic of Dr. Michael McCarty, is now offering ... is the answer for those who need dental work ... procedures have made it safe and comfortable for people ... memories of a painful experience. Dr. Michael McCarty from ...
... Calif. Investigators at the Stanford University School of ... fine-tune the ,activity of individual proteins in cells and ... identifying more precisely than ever ,before the ... could help to speed the development of therapies ,in ...
Cached Medicine News:Health News:MS patients have higher spinal fluid levels of suspicious immune molecule 2Health News:MS patients have higher spinal fluid levels of suspicious immune molecule 3Health News:Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter 2Health News:Jackson Healthcare Forms New Operating Company to Acquire and Manage Hospitals 2Health News:LegalView Re-launching Truck Accident Injury Information Portal with Updated News and Information on the Costly and Dangerous Accidents 2Health News:LegalView Re-launching Truck Accident Injury Information Portal with Updated News and Information on the Costly and Dangerous Accidents 3Health News:Austin Dentistry Clinic Now Offers Certified Full Service Sedation Dentistry -- All Gain, No Pain 2Health News:New way to control protein activity could lead to cancer therapies 2Health News:New way to control protein activity could lead to cancer therapies 3
... The menu-driven Vapro osmometer determines osmolality ... natural equilibrium. ,What you don't get are ... particles, or other conditions that interfere with ... percent in the clinical range) Vapro osmometer ...
... Colloid Osmometer. Rapid measurement of colloid ... of edema onset in clinical situations. ... and reference chambers to simulate the ... in the establishment of osmotic pressure ...
... Automated Cortisol assay ... increased laboratory workflow, Excellent correlation ... assay provides confidence,in assay performance, ... Serum Reference Panels delivers assurance ...
Quantitative determination of cortisol levels in serum and urine. Cross-reactivity with dexamethasone: 0.2% (suppression test).Time to first result: 30 minutes....
Medicine Products: